Clinical Trials Logo

Lymphoma, T-Cell clinical trials

View clinical trials related to Lymphoma, T-Cell.

Filter by:

NCT ID: NCT05149170 Recruiting - Clinical trials for Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in early-stage low-risk extranodal NK/T cell lymphoma, nasal type

NCT ID: NCT05140382 Completed - Clinical trials for Relapsed/Refractory Peripheral T-cell Lymphoma

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Start date: December 15, 2021
Phase: Phase 2
Study type: Interventional

This is a modular dose confirmation and expansion study. The core study design is to assess the efficacy of AZD4573, administered as monotherapy or combination therapy, to participants with either r/r PTCL or r/r cHL and to confirm the safety profiles and PK in these populations. Module 1 of this study will evaluate the efficacy, safety, and tolerability of AZD4573 monotherapy in participants with r/r PTCL or r/r cHL. If AZD4573 monotherapy is found to have promising anti-tumour efficacy in Module 1, an AZD4573 monotherapy Phase II expansion may be added via a substantial protocol amendment.

NCT ID: NCT05138458 Suspended - Mycosis Fungoides Clinical Trials

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

IMAGINE
Start date: December 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.

NCT ID: NCT05137847 Completed - Clinical trials for Lymphoma, T-cell, Cutaneous

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Start date: May 24, 2021
Phase:
Study type: Observational

The primary purpose of the study is to investigate the incidence of adverse drug reactions (ADRs) (ADR of special interest: capillary leak syndrome, infusion reaction, rhabdomyolysis, myelosuppression, infection, hepatic dysfunction, visual impairment/color blindness, ischemic heart disease/arrhythmia/cardiac failure, and severe skin disorders).

NCT ID: NCT05131438 No longer available - Clinical trials for Extranodal NK/T-cell Lymphoma

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

Start date: n/a
Phase:
Study type: Expanded Access

This program is intended to provide access to sugemalimab for participants with R/R ENKTL, after their disease failed to respond to prior treatment regimen(s), preceding marketing authorization by the local regulatory agency.

NCT ID: NCT05127135 Recruiting - Clinical trials for T-cell Non-Hodgkin Lymphoma

Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

Start date: January 22, 2020
Phase: Phase 1
Study type: Interventional

This is a single dose escalation study to evaluate the safety and clinical activity of ThisCART7(Allogeneic CAR-T targeting CD7) in patients with refractory or relapsed CD7 positive T cell malignancies.

NCT ID: NCT05105412 Not yet recruiting - Clinical trials for Peripheral T-cell Lymphomas (PTCL)

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

Start date: October 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single country multi-center, open-label phase Ib/II single-arm study in relapsed or refractory PTCL patients. Patients will be treated with the combination of lenalidomide and gemcitabine until disease progression, intolerable toxicity, or patient withdrawal.

NCT ID: NCT05083208 Recruiting - Clinical trials for Peripheral T-Cell Lymphoma

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Start date: February 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective single-arm, multicenter, phase Ib/II clinical trial of PI3Kδ inhibitor Parsaclisib combined with chidamide for the treatment of relapsed/refractory peripheral T-cell lymphoma.

NCT ID: NCT05079282 Recruiting - Clinical trials for Relapsed or Refractory T Cell Lymphoma

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Start date: December 10, 2021
Phase: Phase 1
Study type: Interventional

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

NCT ID: NCT05075460 Recruiting - T-cell Lymphoma Clinical Trials

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Start date: October 1, 2021
Phase: Phase 3
Study type: Interventional

This is a prospective, multicenter, phase III study of Tucidinostat, Azacitidine combined with CHOP versus CHOP in patients with untreated peripheral T-cell lymphoma